The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Tracking the earliest pathologic changes in Alzheimer disease
Abstract
A current challenge in Alzheimer disease (AD) research is to identify the sequence of pathologic changes that occurs during preclinical stages of disease in advance of cognitive decline. The timing of appearance of the 2 pathologic hallmarks of AD-amyloid deposition and tau-mediated neurodegeneration-is a particular topic of debate, with researchers drawing on a broad range of genetic, neuroimaging, fluid biomarker, animal, and autopsy studies to piece together the series of events ultimately leading to the plaques, neurofibrillary tangles, and cognitive deficits that define AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AD pathology occurs well before (up to two decades) the onset of clinical symptoms2–4.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [4]
In the citing paper
“Research from our laboratories11,12,34 and many others2,4,8,10 has shown that inefficient glucose utilization (and thus impaired ATP production) and oxidative damage are intimately related.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [4]
In the citing paper
“As mentioned earlier, brain pathology in patients who will eventually develop AD probably begins at least two decades before clinical symptoms appear2,4.”
From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [4]
Citations
Cites
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 1×
“The amyloid cascade hypothesis proposes that amyloid is usually the first detectable biomarker, based on current CSF and neuroimaging detection sensitivity.(1,2) Support for this model comes from cross-sectional and longitudinal biomarker studies in familial and sporadic AD showing that amyloid appears about 5–10 year…”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Fleisher, A. S., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B., Ayutyanont, N., Roontiva, A., Thiyyagura, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70227-2 · Cited by 242
Aβ-independent processes—rethinking preclinical AD
Chételat, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.21 · Cited by 184
Brain injury biomarkers are not dependent on β‐amyloid in normal elderly
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23816 · Cited by 183 · cited 1×
“However, a subset of cognitively normal individuals develops neurodegeneration first.(6) It is unclear whether such degeneration is the antecedent to AD, as neurodegeneration with accumulation of tau aggregate occurs in variety of other diseases such as hippocampal sclerosis, cerebrovascular disease, frontotemporal de…”
BackgroundRates of β-amyloid accumulation are independent of hippocampal neurodegeneration
Jack, C. R., Wiste, H. J., Knopman, D. S., Vemuri, P., Mielke, M. M., Weigand, S. D., Senjem, M. L., Gunter, J. L., Lowe, V. J., Gregg, B. E., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000386 · Cited by 141 · cited 2×
“In this issue of Neurology®, Jack et al.8 begin to address this question by examining both amyloid deposition (measured by Pittsburgh compound B–PET imaging) and neurodegeneration (measured by hippocampal volume and atrophy across a set of AD-specific regions) in a group of 252 cognitively normal individuals.”
Background
Cited by
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954
Butterfield, D. A., & Boyd-Kimball, D. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170543 · Cited by 403
“It is now widely accepted that neuropathology of AD occurs in brain approximately two decades prior to onset of clinical cognitive impairments [154].”
BackgroundGeorgieva, E. R., Xiao, S., Borbat, P. P., Freed, J. H., & Eliezer, D. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2014.07.046 · Cited by 133
Butterfield, D. A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101049 · Cited by 108
Amyloid-β Increases Tau by Mediating Sirtuin 3 in Alzheimer’s Disease
Yin, J., Han, P., Song, M., Nielsen, M., Beach, T. G., Serrano, G. E., Liang, W. S., Caselli, R. J., & Shi, J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0977-0 · Cited by 92
Metadata
- Authors
- Landau, S. M., & Frosch, M. P.
- Affiliations
- Harvard University (US)
- ORCID
- Frosch, Matthew P.
- Venue
- Neurology
- Published
- 2014-05-06
- Volume
- 82
- Issue
- 18
- Pages
- 1576-1577
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2023887783
- Cited by
- 20
- References
- 8
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 1 · 2020: 5 · 2019: 2 · 2018: 4 · 2016: 1 · 2015: 3 · 2014: 2
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, preclinical Alzheimer's disease, amyloid deposition, neurofibrillary tangles, amyloid plaques, cognitive decline, biomarkers, neuroimaging
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tracking the earliest pathologic changes in Alzheimer disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000000392
- The paper
- Landau, S. M., & Frosch, M. P. (2014). Tracking the earliest pathologic changes in Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0000000000000392
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.